Q-Line Biotech Limited
1. Overview
Q-Line Biotech Limited (QLBL) is a Lucknow, Uttar Pradesh-based in-vitro diagnostics (IVD) company incorporated in November 2010 as "POCT Services Private Limited" and converted to a public limited company in February 2025. The company is engaged in the manufacturing, trading, and distribution of reagents, medical equipment, and diagnostic instruments for a diverse range of diagnostic applications including clinical chemistry, haematology, coagulation, HPLC, rapid/ELISA, and molecular diagnostics.
QLBL serves diagnostic service providers, hospitals, pathology labs, and medical colleges across 26 states and Union Territories in India, with an established network of distributors, healthcare institutions, and hospital systems. The company has established 4 manufacturing facilities — 3 in Lucknow and 1 in Delhi (Bawana Industrial Area) — supported by ISO 13485:2016 and ISO 9001:2015 certifications. A fourth manufacturing facility was commissioned in February 2026, focused on reagent production.
The IVD market in India is expected to grow at a CAGR of approximately 12.2% to reach USD 2,978 million by CY2030, driven by rising diagnostic demand, preventive healthcare, and chronic disease burden.
2. Business Model and Revenue Streams
Revenue Segments
QLBL operates two primary business lines:
1. Reagents Business (~67–69% of revenue)
- Consumables including reagent kits, rapid cards, POC strips, and immunodiagnostic reagents used in clinical settings
- Breakdown by test type (standalone basis, 2025): Clinical Chemistry ₹113.14 crore (64%), Haematology ₹50.86 crore (29%), Rapid/ELISA ₹8.79 crore (5%), others ~2%
- Fourth manufacturing unit commissioned February 2026 adds ~1.5 million units of Clinical Chemistry Reagent capacity and 75.5 million Rapid/ELISA kits annually
2. Diagnostic Instrument Business (~24–27% of revenue)
- Manufacturing and trading of clinical chemistry analysers, haematology analysers, and point-of-care devices
- Key product: Selectra PRO M fully automatic biochemistry analyser — manufactured in-house at Lucknow under a Technology Transfer Agreement (TTA) with European partners
- Clinical Chemistry Analyser revenue: ₹76.16 crore (2025), Haematology Analyser: ₹32.93 crore
3. Services (~2.6% of revenue)
Annual Maintenance Contracts: ₹8.22 crore in FY2025
Geographic Concentration (Revenue)
| Region | 2025 (₹ Cr) | % |
|---|---|---|
| North (primarily UP) | 252.62 | 80.5% |
| East | 24.88 | 7.9% |
| Central | 14.69 | 4.7% |
| South | 13.22 | 4.2% |
| West + Export | 8.38 | 2.7% |
Uttar Pradesh alone contributes ~72% of revenue, presenting both a concentration risk and a near-term expansion opportunity as the company diversifies into underserved southern and western geographies.
Customer Concentration
- Top 10 customers contributed ₹257.79 crore (82%) of FY2025 revenue
- Total active customers: 963 in FY2025 (of which 545 were repeat customers = 56% repeat rate)
- Company served 1,642 unique customers across the last three fiscal years
Related Party Revenue
QLBL conducts a significant portion of its trading operations through POCT Services (a partnership firm in which a director is a partner), which contributed ₹197.48 crore (~63%) of FY2025 revenue. This represents a material related-party dependency and a key risk investor should assess for governance comfort.
3. Products and Service Portfolio
Manufacturing Products
| Product Category | Key SKUs | Capacity (Annual) |
|---|---|---|
| Clinical Chemistry Reagents | Calibrators, substrates, enzyme kits | ~1.5 million kits (post Unit 4) |
| Haematology Reagents | Diluents, lysing agents, cleaners | ~1.4 million kits |
| Rapid/ELISA Kits | Immunoassay rapid cards | ~75.5 million units (post Unit 4) |
| Selectra PRO M Analyser | Biochemistry analyser (Make in India) | 1,200 units/year |
| Glucometer Devices & Strips | POC glucose monitoring | 31,200 units / 93.6 million strips |
Capacity Utilisation
Lucknow Plant (Selectra PRO M — Manufacturing Unit 2):
| Period | Installed Capacity (units) | Utilised | Utilisation |
|---|---|---|---|
| FY2024 | 400 | 99 | 25% |
| FY2025 | 1,200 | 860 | 72% |
| Dec 2025 | 900* | 498* | 55%* |
*not annualised
Delhi Plant (Clinical Chemistry Reagents & Rapid/ELISA — Unit 3):
| Period | Installed Capacity (kits) | Utilised | Utilisation |
|---|---|---|---|
| FY2023 | 12,72,000 | 3,51,322 | 28% |
| FY2024 | 12,72,000 | 3,91,234 | 31% |
| FY2025 | 12,72,000 | 5,71,909 | 45% |
| 9M Dec 2025 | 9,54,000* | 6,16,633* | 65%* |
*not annualised
Technology Transfer Agreements (TTAs)
QLBL has TTAs with global diagnostic companies for:
- Selectra PRO M — Fully automatic biochemistry analyser (in production; royalty payable)
- Selectra PRO XL — High-throughput analyser (prototype in development; "Make in India")
- Microlab 300 — Semi-automatic analyser (under regulatory approval; expected commercial launch FY27)
- Medonic M-20 — Three-part haematology analyser (prototype complete; commercial production Q2 FY27)
- KC1 Delta — Coagulation analyser (prototype under review)
- Innolyte — Electrolyte analyser (commercial production commenced March 2026)
Average TTA duration is 10 years.
In-House R&D Products
- Q-Count 5 — 5-part haematology analyser (under development)
- Slide Stainer — Indigenously developed; commercial production expected Q3 FY27
4. Key Business Strengths
- Established manufacturing capability with R&D focus: Operates ISO 13485:2016 and ISO 9001:2015 certified facilities with dedicated in-house R&D and 19 R&D staff, enabling "Make in India" reverse-engineering and new product development.
- Diversified IVD product portfolio: Coverage across clinical chemistry, haematology, coagulation, HPLC, rapid/ELISA, molecular, and POC diagnostics reduces segment-specific demand risk.
- Deep North India distribution network: Dominant presence in UP (72–75% of revenue), with 963 active customers and 26-state distribution reach including hospitals, diagnostic chains, and government institutions.
- Technology partnerships with global diagnostic OEMs: Ten-year TTAs with European diagnostic manufacturers provide access to proven technologies, manufacturing know-how, and global quality standards.
- Experienced promoter and management team: Promoter Saurabh Garg (CMD) has ~15 years in the IVD industry; CFO and CS in place since July 2025 strengthening governance.
5. Future Growth Strategy
- Geographic expansion: Increasing penetration in South, West, and Central India regions, which currently contribute less than 12% of revenue, through new distributor appointments and deeper hospital relationships.
- Expanding product portfolio: Introducing new formulations in reagents (immunodiagnostics, medico-plastics), entering new instrument categories (haematology, coagulation), and scaling Glucometer devices and strips.
- IPO-funded working capital and debt reduction: Deploying ₹93.50 crore for working capital and ₹90.00 crore for debt repayment to reduce leverage (D/E: 0.87x in FY2025) and support revenue growth targets of ₹315–470 crore through FY2027–28.
- CDMO business scale-up: Commissioning of the fourth manufacturing unit at Amausi Industrial Area, Lucknow, dedicated to CDMO operations and reagent scale-up, is expected to support third-party manufacturing revenue.
- New instrument launches: Commercialising the indigenously developed Innolyte, Medonic M-20, Microlab 300, and KC1 Delta analysers through FY2026–27 to capture higher-margin instrument placements and associated reagent pull-through revenues.
- Import substitution through "Make in India": Replacing imported reagents and instruments (which constituted ~60% of purchases in FY2025) with domestically manufactured alternatives, thereby improving gross margins and supply-chain resilience.
